Literature DB >> 1856126

Activity of clindamycin against Staphylococcus aureus and Staphylococcus epidermidis from four UK centres.

D S Reeves1, H A Holt, I Phillips, A King, R S Miles, R Paton, R Wise, J M Andrews.   

Abstract

MICs of penicillin, methicillin, clindamycin, erythromycin, sodium fusidate and gentamicin were determined by an agar dilution method for 300 current isolates of Staphylococcus aureus and 100 of S. epidermidis, collected from four centres, and 38 stock strains of methicillin-resistant S. aureus (MRSA). All but one of the 300 current isolates of S. aureus were sensitive to clindamycin (MIC less than 0.5 mg/l), with an MIC90 of 0.12 mg/l. Of a total of 39 MRSA strains, 11 (28.2%) were resistant to clindamycin (MIC greater than 32 mg/l); all of these strains were also resistant to erythromycin. Ten of the 100 strains of S. epidermidis were resistant to clindamycin; they came from a reasonably equal geographical distribution and were also resistant to erythromycin. The results suggest that clindamycin might still be useful as a second-line agent for infections caused by S. aureus and S. epidermidis, although its activity against MRSA was limited to approximately two-thirds of the MRSA strains tested in this study.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1856126     DOI: 10.1093/jac/27.4.469

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

Review 1.  State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development.

Authors:  Venkata Yellepeddi; Joseph Rower; Xiaoxi Liu; Shaun Kumar; Jahidur Rashid; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2019-01       Impact factor: 6.447

2.  Gelatin Nanoparticles for Targeted Dual Drug Release out of Alginate-di-Aldehyde-Gelatin Gels.

Authors:  Sophie Schrade; Lucas Ritschl; Regine Süss; Pia Schilling; Michael Seidenstuecker
Journal:  Gels       Date:  2022-06-08

3.  The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper.

Authors:  Andrew E Simor; Mark Loeb
Journal:  Can J Infect Dis       Date:  2004-01

4.  Phase composition control of calcium phosphate nanoparticles for tunable drug delivery kinetics and treatment of osteomyelitis. II. Antibacterial and osteoblastic response.

Authors:  Vuk Uskoković; Tejal A Desai
Journal:  J Biomed Mater Res A       Date:  2012-10-31       Impact factor: 4.396

5.  Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.

Authors:  Christoph P Hornik; Huali Wu; Andrea N Edginton; Kevin Watt; Michael Cohen-Wolkowiez; Daniel Gonzalez
Journal:  Clin Pharmacokinet       Date:  2017-11       Impact factor: 5.577

6.  Pharmacokinetics of Clindamycin in Obese and Nonobese Children.

Authors:  Michael J Smith; Daniel Gonzalez; Jennifer L Goldman; Ram Yogev; Janice E Sullivan; Michael D Reed; Ravinder Anand; Karen Martz; Katherine Berezny; Daniel K Benjamin; P Brian Smith; Michael Cohen-Wolkowiez; Kevin Watt
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.938

7.  Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants.

Authors:  Daniel Gonzalez; Paula Delmore; Barry T Bloom; C Michael Cotten; Brenda B Poindexter; Elisabeth McGowan; Karen Shattuck; Kathleen K Bradford; P Brian Smith; Michael Cohen-Wolkowiez; Maurine Morris; Wanrong Yin; Daniel K Benjamin; Matthew M Laughon
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.938

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.